Meet
Brian Leinwand

Brian Leinwand provides strategic health economics support throughout a product’s life-cycle and helps clients build evidence packages that demonstrate and support the value of their products.

Brian’s area of specialization is economic modeling, and he has developed models to determine the budget impact of continuous glucose monitoring for Type 1 diabetes and global fibroid ablation for the treatment of uterine fibroids, among others.

Prior to joining Avalere, Brian served as a research assistant, at both the University of North Carolina at Chapel Hill and GlaxoSmithKline, and as a health services researcher at Community Care of North Carolina.

Brian has PhD in pharmaceutical sciences, an MPH in health policy and management, and a BA in management and society from the University of North Carolina at Chapel Hill. Brian is a member of the International Society of Pharmacoeconomics and Outcomes Research and Academy Health.

Authored Content


On June 9, Avalere experts discussed new data analytics and approaches for evaluating value-based topics in healthcare in the “New Data Approaches for Novel Curative Therapies & APMs” webinar. They examined the current approaches to assessing the value of treatments, novel curative therapy affordability and access, and the role of data in healthcare decision-making.

Avalere experts discussed new data analytics and health economics and outcomes research approaches for evaluating key value-based topics in healthcare, including novel curative therapy affordability and access, alternative payment models, and the increasingly important role of real-world evidence in healthcare decision-making.

ICER’s reliance on the average number of FDA drug approvals to calculate budget impact thresholds leads to significant variability.

Today, Avalere published a technical appendix to the PPVF Version 1.0 methodology report, outlining a quantitative method for incorporating patient preferences into value assessments and healthcare decision making.